Drug Trial Radar · NCT01623609
Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol
Last checked: Nov 20, 2026Latest source record: Oct 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Jul 2012
Primary completion
Sep 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 20, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the Bioequivalence, assess food administration on the Pharmacokinetics with naloxegol.
Conditions
- Opioid Induced Constipation
Interventions
NaloxegolDrug
Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
NaloxegolDrug
Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Description of the pharmacokinetic (PK) profile for naloxegol in terms of maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC) for each treatment period.Time frame: Predose,0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.